Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines by Dongsheng Yue et al.
Yue et al. BMC Cancer 2014, 14:422
http://www.biomedcentral.com/1471-2407/14/422RESEARCH ARTICLE Open AccessSurvival analysis of patients with non-small cell
lung cancer who underwent surgical resection
following 4 lung cancer resection guidelines
Dongsheng Yue, Liqun Gong, Jian You, Yanjun Su, Zhenfa Zhang, Zhen Zhang, Feng Gu, Meng Wang
and Changli Wang*Abstract
Background: To compare survival of patients with non-small cell lung cancer (NSCLC) who underwent surgical
resection and lymph node sampling based on guidelines proposed by the American College of Surgeons Oncology
Group (ACOSOG), National Comprehensive Cancer Network (NCCN), the OSI Pharmaceutical RADIANT trial, and the
International Association for the Study of Lung Cancer (IASLC).
Methods: Medical records of patients with NSCLC who underwent surgical resection from 2001 to 2008 at our
hospital were reviewed. Staging was according to the 7th edition of the AJCC TNM classification of lung cancer.
Patients who received surgical resection following the IASLC, ACOSOG, RADIANT or NCCN resection criteria were
identified.
Results: A total of 2,711 patients (1803 males, 908 females; mean age, 59.6 ± 9.6 years) were included. Multivariate
Cox proportional hazards regression analysis indicated that increasing age, adenosquamous histology, and TNM
stage II or III were associated with decreased overall survival (OS). Univariate analysis and log-rank test showed that
surgical resection following the guidelines proposed by the IASLC, NCCN, ACOSOG, or RADIANT trial was associated
with higher cumulative OS rates (relative to resection not following the guidelines). Multivariate analysis revealed
that there was a significant improvement in OS only when IASLC resection guidelines (complete resection) were
followed (hazard ratio = 0.84, 95% confidence interval 0.716 to 0.985, P = 0.032).
Conclusions: Surgical resection following the criteria proposed by IASLC, NCCN, ACOSOG, or the RADIANT trial was
associated with a higher cumulative OS rate. However, significant improvement in OS only occurred when IASLC
resection guidelines were followed.
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Lung cancer is the leading cause of cancer-related mortal-
ity in men and women in the United States and throughout
the world [1]. In the United States, an estimated 228,190
new cases of lung cancer are expected in 2013, accounting
for about 14% of cancer diagnoses [2]. Further, an esti-
mated 159,480 deaths due to lung cancer are expected to
occur, accounting for approximately 27% of all cancer* Correspondence: wangchangli@medmail.com.cn
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unless otherwise stated.deaths [2]. Non-small cell lung carcinoma (NSCLC)
accounts for approximately 85% of all lung cancers in
the United States [2]. In China, lung cancer has the
highest incidence (53.57/100,000 in 2009) and mortality
(45.57/100,000 in 2009) among all cancers [3]. Most lung
carcinomas are diagnosed at an advanced stage and, as
such, have a poor prognosis. The 5-year relative survival
rates vary with the stage of disease at diagnosis, with re-
ported rates being 49% for local disease, 16% for regional
disease, and 2% for distant disease [4].
Accurate staging is a critical aspect of the diagnostic
work-up of patients with NSCLC, with disease stage
influencing decisions regarding the type and timing of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment for patients with stage I and II NSCLC [6,7].
The role of surgery for stage III disease is controversial,
while patients with stage IIIB or IV tumors are rarely
surgical candidates [7]. Cerfolio et al [8] reported that
about 14% NSCLC patients were clinically over-staged
(benign nodules) and 32% were clinically under-staged
(most from nonimaged N2 disease). Based on their report,
only 56% of patients clinically staged as having stage I
NSCLC had pathologic stage I disease while 6.8% of
patients clinically staged as having greater than stage
I had pathologic stage I disease, suggesting that complete
thoracic lymphadenectomy improve the staging of patients
with NSCLC.
Curative treatment of early stage NSCLC requires
good quality surgical resection (GQR); however, some
issues of contention exist. On the one hand, the findings
from a previous study suggest that the degree of compli-
ance with national recommendations for GQR is poor,
and that the majority of curative-intent resections of
early stage NSCLC did not achieve GQR standards [9].
On the other hand, there is no consensus as to what
constitutes a minimally acceptable degree of surgical
resection [9]. GQR guidelines have been proposed by
a number of groups, including the International Associ-
ation for the Study of Lung Cancer (IASLC) [10], American
College of Surgeons Oncology Group (ACOSOG) [11],
National Comprehensive Cancer Network (NCCN) [12],
and OSI Pharmaceutical RADIANT trial [9,12] (note:
the RADIANT trial is an ongoing trial of erlotinib
after surgery with or without adjuvant chemotherapy
in patients with NSCLC epidermal growth factor receptor
positive tumors [12]). The IASLC, NCCN, ACOSOG, and
RADIANT resection guidelines all require negative sur-
gical margins as determined microscopically, but differ in
the degree of lung resection and lymph node sampling
and resection [7,9-12]. Lymph node status is closely asso-
ciated with prognosis in patients with NSCLC and is an
important component of the lung cancer staging classifi-
cation system [13-15]. However, the extent of lymph node
removal required and the impact of mediastinal node
removal on survival are controversial [16]. The NCCN,
ACOSOG, and RADIANT resection guidelines require
certain degrees of lymph node sampling [7,11,12]. How-
ever, the IASLC guidelines indicate that complete re-
section of lymph nodes should be performed instead
of lymph node sampling [15].
The major differences between the IASLC, NCCN,
ACOSOG, and RADIANT resection guidelines are the
degree of lung resection and lymph node sampling versus
resection [7,10-12]. The ACOSOG requires examination
of station 10 (hilar lymph nodes) in addition to other N1
nodes, and at least 1 lymph node from stations 2, 4, and 7
for right-sided tumors or stations 5, 6, and 7 for left-sidedtumors [11]. The NCCN criteria require N1 and N2 lymph
node resection and mapping with sampling from a mini-
mum of 3 N2 stations [7]. The RADIANT study criteria
requires at least 2 mediastinal stations be sampled, though
the exact stations are not specified and N1 sampling is not
required [12]. Instead of sampling, the IASLC requires sys-
tematic nodal dissection or lobe-specific systematic nodal
dissection, no extracapsular involvement of the tumor, and
the highest mediastinal node removed must be negative
[10]. Thus, surgical resection that follows the IASLC GQR
guidelines would also meet the criteria proposed by other
GQR guidelines.
The purpose of this study was to compare survival in
patients with NSCLC by the resection guideline followed
(all four aforementioned guidelines were included to assess
whether differences in criteria affect outcomes). The fac-
tors associated with survival and the cumulative survival
rate were compared. Also, since more surgeons performed
complete lymphadenectomy without lymph node sam-
pling (IASLC guidelines) after 2005, we aimed to determine
whether this change in surgical procedure would affect the
survival of the NSCLC patients.
Methods
Participants
In this study, the medical records of patients with NSCLC
who underwent surgical resection from 2001 to 2008 at
Tianjin Medical University Cancer Institute and Hospital,
were reviewed. This study was approved by the Institu-
tional Review Board of Tianjin Medical University Cancer
Institute and Hospital. Due to the retrospective nature of
the study, the requirement for informed patient consent
was waived. Patients were included in the study if they
had a diagnosis of NSCLC confirmed by pathological tis-
sue examination and underwent surgical resection. Exclu-
sion criteria were: 1) Staging data was not available; 2)
Data to determine which surgical resection guideline
followed was not available; (3) Received radiotherapy be-
fore resection; (4) Secondary malignancy identified within
5 years after resection; (5) Incomplete follow-up data.
Data collection
Data extracted from the medical records included age,
gender, smoking history, surgical procedure, surgical mar-
gin status, histological diagnosis, T stage, N stage, TNM
stage, number of lymph node stations examined, number
of lymph nodes removed, and treatments (i.e., surgical
resection, adjuvant chemotherapy, radiotherapy or immu-
notherapy). Patients were restaged according to the 7th
edition of the American Joint Committee on Cancer
(AJCC) TNM classification of lung cancer [10]. Patients
who received surgical resection following the IASLC,
ACOSOG, RADIANT, or NCCN resection criteria were
identified. In addition, patients were divided into 2 time
Table 1 Demographic and clinical characteristics of subjects
(N = 2711)
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Lymph node stations examined
< 6 group 1040 (38.4)
≥ 6 group 1671 (61.6)
Number of lymph nodes removed
< 10 689 (25.4)
10-20 943 (34.8)
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period from 2001 to 2004, when lymph node sampling
was performed by most surgeons at our hospital; Period
II: those who received surgery during the period from
2005 to 2008, when more surgeons performed complete
resection following the definition proposed by the IASLC
[10]. The IASLC requires: that the free resection margins
be proven microscopically; systematic nodal dissection
or lobe-specific systematic nodal dissection; no extra-
capsular nodal extension of the tumor; and that the
most distant nodal stations (the highest in the superior
paratracheal and the lowest in the pulmonary ligament)
are negative [10].
Statistical analysis
Demographics and clinical characteristic of the subjects
are summarized as mean ± standard deviations (SD) for
continuous variables and number (%) for categorical
variables. Univariate and multivariate Cox proportional
hazards regression analyses were carried out to identify
factors having a significant impact on overall survival
(OS). Significant variables (P < 0.05) in univariate Cox
proportional hazards regression analysis were entered
into multivariate analysis. The associated results are
reported as hazard ratios (HRs) with 95% confidence in-
tervals (CIs). Kaplan-Meier curves of OS are presented
for the cumulative survival rates versus follow-up time
for patients in whom the 4 lung cancer resection guide-
lines were or were not followed. The log-rank test was
performed to identify differences in OS between patients
in which the 4 resection guidelines were or were not
followed. The cumulative 6-month and 1-, 3-, and 5-year
survival rates with corresponding 95% CIs were also
determined for patients in which the 4 resection criteria
were or were not followed. All statistical assessments
were 2-tailed. A value of P < 0.05 was considered to
indicate statistical significance. Statistical analyses were
performed using SPSS 18.0 statistics software (SPSS Inc,
Chicago, IL, USA).
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the sub-
jects are shown in Table 1. The records of 3,346 patients
were reviewed, and a total of 2,711 NSCLC patients
(1803 males, 908 females) with a mean age of 59.6 ±
9.6 years were included in the analysis after applying the
inclusion and exclusion criteria. Of the included patients,
83.1% received lobectomy. The majority of patients (50.4%)
had a histological diagnosis of squamous cell carcinoma
and adenocarcinoma was second most common (34.1%).
The majority of patients (42.5%) were at stage I and those
at stage III followed (32.9%). Fewer than 6 lymph node
stations were examined in almost 40% of patients. Twenty
Table 1 Demographic and clinical characteristics of subjects







Data are presented as mean ± standard deviation (SD) or number (percentage).
*1151 patients were classified into stage I, 669 in stage II, and 891 in stage III.
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patients and fewer lymph nodes removed in the remaining
patients. The majority of patients received adjuvant che-
motherapy after the surgical treatment and fewer patient
received radiotherapy and immunotherapy.Cox proportional hazards regression analysis
The results of the Cox proportional hazards regression
analysis of potential factors affecting OS are shown in
Table 2. Univariate analysis revealed that age, surgical
procedure (pneumonectomy vs. segmentectomy), positive
surgical margins, histological diagnosis (adenocarcinoma
vs. squamous and squamous vs. adenosquamous), TNM
stage II/III, < 6 lymph node stations examined, number of
lymph nodes removed (<10 vs. ≥ 20), and a lack of radio-
therapy were associated with decreased OS (all P < 0.05).
In contrast, resection in accordance with IASLC, ACO-
SOG, RADIANT, and NCCN guidelines (vs. resection not
in accordance with these guidelines) was associated with
improved OS (P < 0.001).
Variables with a significant association (P < 0.05) in
univariate Cox proportional hazards regression analysis
were included in the multivariate analysis, which revealed
that advanced age, adenosquamous histology and TNM
stages II or III were associated with decreased OS. Use of
IASLC resection guidelines (complete resection) was
associated with increased OS in comparison to not using
IASLC guidelines.Kaplan-Meier curves of OS
Patients’ estimated median survival time was 50 months
and the cumulative 6 month and 1-, 3-, and 5-year sur-
vival rates were 95%, 86%, 60% and 45%, respectively
(Table 3). The cumulative survival rates with correspond-
ing 95% CIs for patients in which the 4 surgical resection
guidelines were or were not followed are also summarized
in Table 3. Figure 1 shows the Kaplan-Meier curves for
the cumulative survival rates versus follow-up time for the
entire cohort of patients in which the 4 resection guide-
lines were or were not followed. OS was significantly
longer for patients for whom the guidelines were followedcompared to patients in whom the guidelines were not
followed (all P < 0.05) (Figure 1).
Table 4 presents the number of patients for whom the
4 resection guidelines were followed during the periods
from 2001 to 2004 (29.6%) and from 2005 to 2008
(56.4%), representing a significant increase between the
two periods. Note: a greater proportion of curative-intent
surgical resections complied with GQR guidelines (IASLC,
NCCN, ACOSOG, or RADIANT) between 2005 to 2008.
The Kaplan-Meier curves of the cumulative survival for
the periods from 2001 to 2004 and 2005 to 2008 are
shown in Figure 2. The cumulative survival rate was
greater in the period from 2005 to 2008 than in the period
from 2001 to 2004 (log-rank test, P < 0.05). The total
number of patients in whom the 4 resection guidelines
were followed includes 43.7% following IASLC resection
guidelines, 59.5% following ACOSOG guidelines, 77% fol-
lowing RADIANT guidelines and 59.3% following NCCN
guidelines (Figure 2).
Discussion and conclusions
This study showed that surgical resection of NSCLC
without following the GQR guidelines proposed by the
IASLC, NCCN, ACOSOG, or RADIANT trial did affect
the OS among our NSCLC patients between 2001 and
2008. However, multivariate Cox analysis indicated that
only following IASLC resection guidelines (complete re-
section) was a favorable factor for OS (HR = 0.840, 95%
CI 0.716-0.985, P = 0.032). Our observation is not con-
sistent with that reported by Allen et al. [9], who found
that 3-year survival was not significantly higher among
patients who received resection in accordance with the
GQR guidelines compared with those who did not receive
resection in accordance with the guidelines. The difference
between our finding and that reported by Allen et al. [9]
may be related study population differences, in particular,
the difference in the percentage of patients with stage I
disease. In the study reported by Allen et al. [9], 69% of
patients had stage I disease, whereas in our study, only
42.5% of patients had AJCC stage I disease. Hence, patients
with > stage I disease may derive greater benefit from surgi-
cal resection that complies with the GQR guidelines.
The impact of mediastinal node removal and the ex-
tent of lymph node removal on survival are still being
debated [9]. Some long-term follow-up data suggest that
the 5-year survival rate following complete resections is
unaffected by the nodal strategy, with reported rates of
45% with complete mediastinal lymphadenectomy and
43% when sampling was performed (P = 0.18) [10]. Izbicki
et al. [17] conducted a randomized controlled trial to
compare the survival between mediastinal lymph node
sampling and systematic mediastinal lymphadenectomy.
After a median follow-up of 47 months, it was found
that systematic mediastinal lymphadenectomy did not
Table 2 Univariate and multivariate Cox proportional hazards regression analysis of factors affecting overall survival
(N = 2711)
Univariate Multivariate
Variables HR (95% CI) P value HR (95% CI) P value
Age (y) 1.008 (1.002, 1.013) 0.006* 1.014 (1.008, 1.020) <0.001*
Gender
Female reference
Male 1.017 (0.909, 1.138) 0.774
Smoking history
Never reference
Smoker 1.061 (0.950, 1.185) 0.293
Surgical procedure <0.001* <0.001*
Segmentectomy reference reference
Lobectomy 1.002 (0.709, 1.418) 0.989 0.975 (0.672, 1.413) 0.892
Pneumonectomy 1.451 (1.006, 2.092) 0.047* 1.338 (0.901, 1.986) 0.149
Extended 1.668 (0.892, 3.119) 0.109 1.533 (0.804, 2.921) 0.194
Surgical margin status
Negative reference reference
Positive 1.612 (1.298, 2.004) <.001* 1.200 (0.883, 1.632) 0.243
Histology 0.006* 0.034*
Squamous reference reference
Adenocarcinoma 0.884 (0.785, 0.997) 0.044* 1.000 (0.883, 1.132) 0.999
Large cell 0.912 (0.547, 1.522) 0.726 1.002 (0.600, 1.674) 0.993
Adenosquamous 1.327 (1.067, 1.651) 0.011* 1.347 (1.080, 1.680) 0.008*
Other 1.084 (0.896, 1.312) 0.409 1.208 (0.994, 1.467) 0.057
T stage
T1/T2 reference
T3/T4 1.646 (1.430, 1.895) <0.001*
N stage
N0 reference
N1/N2 1.697 (1.526, 1.887) <0.001*
AJCC TNM Stage <0.001* <0.001*
I reference reference
II 1.612 (1.405, 1.850) <0.001* 1.571 (1.366, 1.808) <0.001*
III 2.172 (1.917, 2.461) <0.001* 2.101 (1.835, 2.405) <0.001*
Lymph node stations examined
≥ 6 group reference reference
< 6 group 1.197 (1.075, 1.333) 0.001* 1.199 (0.771, 1.863) 0.421
Number of lymph nodes removed <0.001* 0.075
≥ 20 reference reference
10-20 0.954 (0.842, 1.082) 0.463 0.935 (0.819, 1.067) 0.318
< 10 1.264 (1.109, 1.441) <0.001* 1.125 (0.943, 1.343) 0.190
Followed IASLC guidelines
Yes 0.715 (0.641, 0.797) <0.001* 0.840 (0.716, 0.985) 0.032*
No reference reference
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Table 2 Univariate and multivariate Cox proportional hazards regression analysis of factors affecting overall survival
(N = 2711) (Continued)
Followed ACOSOG guidelines
Yes 0.816 (0.733, 0.908) <0.001* 1.088 (0.389, 3.045) 0.873
No reference reference
Followed RADIANT guidelines
Yes 0.785 (0.696, 0.885) <0.001* 0.887 (0.735, 1.071) 0.213
No reference reference
Followed NCCN guidelines
Yes 0.814 (0.732, 0.906) <0.001* 1.089 (0.422, 2.811) 0.860
No reference reference
Adjuvant chemotherapy
Yes 0.989 (0.890, 1.099) 0.835
No reference
Radiotherapy
Yes 0.768 (0.671, 0.877) <0.001* 0.915 (0.797, 1.049) 0.203
No reference reference
Immunotherapy
Yes 1.063 (0.83, 1.281) 0.517
No reference
ACOSOG, American College of Surgeons Oncology Group; IASLC, International Association for the Study of Lung Cancer (IASLC); NCCN, National Comprehensive
Cancer Network; RADIANT, OSI Pharmaceutical’s RADIANT study; HR, hazard ratio; CI, confidence interval.
Variables with a significant association with overall survival in univariate analysis (P < 0.05) were selected and put into the multivariate analysis.
Note: Because T stage, N stage, and TNM stage are collinear, only TNM stage was included in the multivariate Cox proportional hazards regression analysis.
*Significant risk factor, P < 0.05.
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patients (34.2% vs. 45.2%), although the rate of recur-
rence tended to be reduced among patients who under-
went complete lymphadenectomy. Allen et al. [18] also
conducted a randomized trial comparing lymph nodeTable 3 Cumulative survival rates of patients in which the 4 lun
1-year 3-y
Overall 0.86 (0.84, 0.87) 0.60
IASLC guidelines
Yes 0.90 (0.88, 0.92) 0.69
No 0.85 (0.84, 0.87) 0.53
ACOSOG guidelines
Yes 0.88 (0.86, 0.9) 0.64
No 0.82 (0.79, 0.84) 0.55
RADIANT guidelines
Yes 0.88 (0.86, 0.89) 0.62
No 0.79 (0.75, 0.82) 0.53
NCCN guidelines
Yes 0.88 (0.86, 0.90) 0.64
No 0.82 (0.79, 0.84) 0.55
ACOSOG, American College of Surgeons Oncology Group; IASLC, International Asso
Cancer Network; RADIANT, OSI Pharmaceutical’s RADIANT study; CI, confidence inte
Results are presented as cumulative survival rate (0.0-1.0) with corresponding 95%
*Significant difference between Yes/No follow guidelines, P < 0.05.sampling versus mediastinal lymph node dissection for
early stage lung cancer and found that there was no
association between the type of resection and mortality.
However, Jonnalgadda et al. [19] performed an analysis of
the SEER database and found that the number of positiveg cancer resection guidelines were or were not followed
ear 5-year P
(0.58, 0.62) 0.45 (0.42, 0.47)
<0.001*
(0.66, 0.71) 0.51 (0.48, 0.54)
(0.58, 0.58) 0.41 (0.38, 0.44)
<0.001*
(0.61, 0.66) 0.47 (0.44, 0.49)
(0.52, 0.58) 0.42 (0.38, 0.45)
<0.001*
(0.6, 0.64) 0.46 (0.43, 0.49)
(0.49, 0.57) 0.40 (0.35, 0.44)
<0.001*
(0.61, 0.66) 0.47 (0.44, 0.49)
(0.52, 0.58) 0.42 (0.38, 0.45)
ciation for the Study of Lung Cancer (IASLC); NCCN, National Comprehensive
rval.
CI.
Figure 1 Kaplan-Meier curves of overall survival (OS) for patients in which the (A) IASLC, (B) ACOSOG, (C) RADIANT, and (D) NCCN GQR
guidelines were or were not followed (+indicates censored cases). The log-rank test showed that OS was significantly different between
patients in which the resection guidelines were followed compared with those in which the guidelines were not followed (all P < 0.001).
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survival in patients with N1 NSCLC, suggesting that
sampling and removing the positive lymph nodes might
improve survival. Verhagen et al. [20] reported that a
complete lymph node dissection according to the European
Society of Thoracic Surgery guidelines for intraoperative
lymph node staging in patients with NSCLC was onlyTable 4 Patients in which the 4 lung cancer resection guidelin
Guideline followed Total (N = 2711) 2001-200
IASLC 1185 (43.7) 381 (29.6)
ACOSOG 1614 (59.5) 560 (43.5)
RADIANT 2088 (77.0) 811 (63.1)
NCCN 1608 (59.3) 555 (43.2)
Data are presented as number (percentage) of patients following the guidelines. Di
Chi-square test.
*Significant difference between the 2 time periods, P < 0.05.performed in 4% of patients. A Cochrane review by Manser
et al. [21] concluded that lesion resection combined
with complete mediastinal lymph node dissection was
associated with a small to modest improvement in survival
compared with systematic sampling of mediastinal nodes
in patients with stage I to IIIA NSCLC. Results of the
multivariate regression analysis of our data showed thates were followed in the 2 periods





fferences between the 2 periods were compared using the Pearson
Figure 2 Kaplan-Meier curves of overall survival (OS) for time period 2001 to 2004 (more surgeons performed lymph node sampling)
(blue line) and 2005 to 2008 (more surgeons performed complete resection) (green line) (+indicates censored cases). P < 0.001 indicates
OS was significantly different between the 2 periods.
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tion) was associated with improved OS. This finding is
consistent with that reported by Manser [21]. Additionally,
in our study, OS was significantly better in the period
from 2005 to 2008 than in the period from 2001 to
2004. Furthermore, the number of resections that met
the IASLC, NCCN, ACOSOG, and RADIANT resection
criteria was significantly greater in the period from 2005
to 2008, highlighting the importance of the quality of
surgical resection.
Our study has some limitations that should be men-
tioned. The first limitation is the retrospective nature of
the analysis, which means we cannot make an evidence-
based conclusion that complete resection provides a sur-
vival advantage. The second limitation is the arbitrariness
of using the year 2005 as a cut-off. However, in fact, the
definition of complete resection was published by the
Complete Resection Subcommittee of IASLC in 2005 [10],which encouraged surgeons to change the surgical proced-
ure for NSCLC.
In summary, the OS rate of patients with early stage
NSCLC can be increased following GQR as defined by the
IASLC, NCCN, ACOSOG, and RADIANT trial. More
surgeons routinely performed complete lymphadenectomy
and there was increased compliance with GQR guidelines
after 2005 at our institution. This may be one of the rea-
sons for the improvement in OS of patients with early
stage NSCLC in recent years.
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